The injection pen market size is projected to reach US$ 74.20 billion by 2031 from US$ 42.70 billion in 2023. The market is expected to register a CAGR of 7.14% in 2023–2031. Primary factors driving the market growth are rising prevalence of chronic disorders such as, cancer, diabetes, stroke, heart disease and arthritis and increase in strategic developments. However, presence of alternate drug delivery devices and inadequate reimbursement policies are restricting the market growth.
An injector pen, also called a medication pen, is a device that is used to inject medication under the skin. Injector pens are designed to make injectable therapy easier and more convenient for patients, aiming to increase patient adherence. Given the additional work involved in administering an injection and the possibility of an adverse reaction to self-injecting medication, this is particularly troublesome with injectable treatments.
A few prevalent and expensive long-term health issues are influenced by societal behavioural shifts and the aging population. The World Health Organization (WHO) projects that by 2026, 57% of people would have a chronic lifestyle condition. Given that developing nations are predicted to have a population increase, emerging markets will be particularly heavily hit. People are more likely to lead sedentary lifestyles as a result of the rapid urbanization, which contributes to obesity and diabetes. One of the main issues facing world health in the twenty-first century is diabetes. The International Diabetes Federation (IDF) estimates that there were roughly 46 million diabetics in North America in 2019 and that figure is expected to rise to 62 million by 2045.
The disease prevalence has increased by almost 35% within the anticipated time frame. In addition, many chronic illnesses like multiple sclerosis, osteoporosis, and cardiovascular diseases necessitate repeated medication administration for illness management. The World Health Organization (WHO) reports that cardiovascular problems account for over 17.9 million fatalities annually, making them the leading cause of death. It is becoming the new norm for injectable drug delivery across a sizable patient base worldwide. Injection pens are widely utilized in home healthcare settings, which contributes to their market growth. Additionally, a large patient population may use them with little training and no ongoing help from healthcare experts.
The presence of multiple market players is a defining feature of the injection pen market. Market participants employ a variety of tactics, including new product releases, regional growth, and technology improvements, to grow their market share. The industry participants are beginning to accept injection pens more because of their growing involvement in ongoing innovation and technical advancements. Prominent firms make R&D investments to create cutting-edge technologies and increase profits.
A few key developments related to injection pen are mentioned below:
Therefore, all the above-mentioned key developments are driving the growth of injection pen market.
Many chronic illnesses, including diabetes, multiple sclerosis, and cancer, are being treated with biologics. These medications are one-of-a-kind in their own right, and the companies who make and sell them are granted 20 years of patent protection. Due to the fact that the majority of patents have either expired or are about to expire, other market participants have started to introduce biosimilars, or their own versions of these medications.
In comparison to the original biologics, biosimilars—low-cost generic medications that are favoured by the government and insurance companies—have become extremely popular in recent years. The prominent market players are promoting the adoption of biosimilars, which further creates the demand for injection pens for its administration. As per AJMC, a total of forty biosimilars were approved and twenty-five new biosimilars were launched in the US till December 2022. Additionally, due to the rapid response, injectables have been used extensively, which has increased demand for injection pens for safety.
In addition, the producers of injection pens are continuously offering instruction on how to use them correctly to prevent complications like needle stick injuries and hypoglycaemia, which is anticipated to further expand the market for injection pen. For instance, Noble, a Aptar Pharma company is the global leader in the medical device training solution which improves the patient experience and outcomes by developing patient-centric drug delivery training devices including injection pen, autoinjector, prefilled syringe and others. Therefore, increased use of biosimilars, patent expiry and increased use of injectables for drug administration are likely to create ample opportunity for the growth of injection pen market in the coming years.
Key segments that contributed to the derivation of the injection pen market analysis are type, therapy, and end user.
The geographic scope of the injection pen market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.
In North America, the Injection Pen market is currently experiencing exponential growth during the forecast years. The US market dominates the global injection pen market in 2023 As per the American Diabetes Association, 37.3 million Americans (or 11.3% of the total population) were diagnosed with diabetes in 2019. Type 1 diabetes affects around 1.9 million people in the US, 244,000 of whom are children and teenagers. Moreover, almost 1.4 million Americans receive a diabetes diagnosis each year. The Centers for Disease Control and Prevention estimate that 88 million adults in the US have prediabetes in 2020, accounting for 34.5% of the adult population. By 2022, almost 30 million Americans will have diabetes, and about 7 million of them will need daily insulin, according to Yale researchers.
There is an increase in demand for infertility treatment in the US. For instance, according to the CDC, in 2019, in the US, 9% of men and 10% of women aged 15 to 44 reported infertility problems. The prominent players are introducing novel products to meet the growing demand for injection pens globally. For instance, Merck KGaA offers a prefilled, ready-to-use pen to administrate GONAL-f for treatment of infertility. Thus, the rise in cases of diabetes and infertility problems and innovative product launches by key players are driving the injection pen market in the US.
The regional trends and factors influencing the Injection Pen Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Injection Pen Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
Report Attribute | Details |
---|---|
Market size in 2023 | US$ 42.70 Billion |
Market Size by 2031 | US$ 74.20 Billion |
Global CAGR (2023 - 2031) | 7.14% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
The Injection Pen Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Injection Pen Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The Injection Pen market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for innovations, business expansion, and strategies:
The “Injection Pen Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:
Injection Pen market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
Injection Pen Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
North America dominated the injection pen market in 2023
The rising prevalence of chronic disorders is the major factors fuelling the market growth of injection pens over the years.
Technological advancements and healthcare waste reduction are likely to remain a key trend in the market.
Eli Lilly and Co, Novo Nordisk AS, Owen Mumford Ltd., Sanofi SA, Merck KGaA, Haselmeier GmbH, Gerresheimer AG, Becton Dickinson and Co., AstraZeneca Plc, Teva Pharmaceutical Industries Ltd
The market is expected to register a CAGR of 7.14% during 2023–2031.